- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gilead Sciences settles patent disputes with Lupin, Cipla and 3 others over HIV, Hepatitis B drugs generic versions
The generic drugmakers argued that the patents were invalid and unenforceable. They said in an August court filing that Gilead's patents covered "routine and predictable" variants of a "compound it did not invent."
US: Gilead Sciences Inc has settled patent disputes with five drugmakers over proposed generic versions of its blockbuster HIV drugs Descovy and Odefsey and hepatitis B drug Vemlidy, it said Monday in a filing with the U.S. Securities and Exchange Commission.
Generic drugmakers Apotex Inc, Lupin Ltd, Cipla Ltd, Macleods Pharmaceuticals Ltd and Hetero Labs Ltd will receive non-exclusive licenses to the patents, allowing them to sell generic versions of the HIV drugs starting in October 2031 and Vemlidy in January 2032, according to the filing.
The filing did not disclose additional settlement details, but said the licenses could begin earlier "in certain circumstances."
A spokesperson for Gilead said the company was pleased with the resolution. A representative for Apotex and attorneys for Lupin and Cipla declined to comment Monday.
The other companies and their attorneys did not immediately respond to requests for comment.
The disclosure came the same day a bench trial was scheduled to begin on Gilead's claims in Delaware federal court. Gilead told U.S. District Judge Maryellen Noreika that it had resolved the cases in a series of filings between Thursday and Sunday.
Foster City, California-based Gilead sold nearly $1.4 billion of Descovy, over $1 billion of Odefsey, and over $380 million of Vemlidy in the United States last year.
Gilead sued the drugmakers for infringement after they requested U.S. Food and Drug Administration approval for their proposed generics. The company requested a ruling that its patents were valid and an order to block the generics until they expired.
The generic drugmakers argued that the patents were invalid and unenforceable. They said in an August court filing that Gilead's patents covered "routine and predictable" variants of a "compound it did not invent."
The drugmakers said in the filing that Gilead's patents would have improperly maintained its monopoly on the drugs until August 2032.
The case is Gilead Sciences v. Apotex Inc, U.S. District Court for the District of Delaware, No. 1:20-cv-00189.
For Gilead: Juanita Brooks of Fish & Richardson
For Apotex: Stephen Auten, Richard Ruzich and Ian Scott of Taft Stettinius & Hollister
For Lupin: William Zimmerman, Jonathan Bachand and Andrea Cheek of Knobbe Martens Olson & Bear
For Macleods: Neal Seth and Adrienne Kosak of Wiley Rein
For Cipla: Jefferson Boggs, Christopher Sorenson, and Andrew Larsen of Merchant & Gould
For Hetero: Dennies Varughese and Joseph Kim of Sterne Kessler Goldstein & Fox
Read also:
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751